Providence Therapeutics Holdings Inc.
$10,000,000.00 CAD
- Department
- National Research Council Canada
- Recipient country
- Canada
- Fiscal year
- 2022-2023
- Agreement period
- September 1, 2022 – March 15, 2023
- Reference
- nrc-cnrc:172-2022-2023-Q3-998413
Published purpose
Providence Therapeutics intends to continue the clinical development of a made-in-Canada mRNA vaccine against COVID-19. The firm is expecting to initiate a Phase 3 clinical trial on PTX-COVID19-B in mid-2023 and pursue market or emergency approvals to commercialize in late 2023 or early 2024. The objective of this project is to facilitate the company's R&D efforts and vaccine development program to begin a Phase 3 clinical trial in 2023.
In plain English AI-generated
Funding supports Providence Therapeutics in advancing clinical development of a Canadian-made mRNA COVID-19 vaccine, including a Phase 3 trial and pursuit of market approvals.
Category: Health Primarily funds activity in Canada
Based on the published description. See how AI categorization works — the linked official record is authoritative.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.